Kyani Sunset Australia - English - Department of Health (Therapeutic Goods Administration)

kyani sunset

kyani australia pty ltd - d-alpha-tocopherol, quantity: 3.36 mg; palm tocotrienols complex, quantity: 88 mg; concentrated fish omega-3 triglycerides, quantity: 200 mg (equivalent: eicosapentaenoic acid, qty 106 mg; equivalent: docosahexaenoic acid, qty 40 mg); natural fish oil, quantity: 112.32 mg (equivalent: docosahexaenoic acid, qty 6.75 mg; equivalent: eicosapentaenoic acid, qty 6.75 mg); colecalciferol, quantity: 8.3 microgram; retinol palmitate, quantity: 458.15 microgram (equivalent: vitamin a, qty 249.9 microgram) - capsule, soft - excipient ingredients: gelatin; purified water; glycerol; soya oil; mixed (low-alpha type) tocopherols concentrate; dl-alpha-tocopherol - antioxidant/reduce free radicals formed in the body ; maintain/support healthy eyesight/vision ; maintain/support cardiovascular system health ; maintain/support healthy immune system function ; maintain/support (state vitamin/mineral/nutrient) levels in the body

LEVETIRACETAM-AFT levetiracetam 500 mg/5 mL concentrate solution for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

levetiracetam-aft levetiracetam 500 mg/5 ml concentrate solution for infusion vial

aft pharmaceuticals pty ltd - levetiracetam, quantity: 10 % w/v - injection, concentrated - excipient ingredients: glacial acetic acid; sodium chloride; water for injections; sodium acetate trihydrate - levetiracetam-aft oral solution is indicated for:,use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation,,monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy.,add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme),and,add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).,levetiracetam-aft concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Omega Cardio Max Australia - English - Department of Health (Therapeutic Goods Administration)

omega cardio max

hazel pharmaceuticals pty ltd - concentrated fish omega-3 triglycerides,cyanocobalamin,folic acid,levocarnitine,pyridoxal 5-phosphate,reynoutria japonica,ubidecarenone -

DOTAX docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

dotax docetaxel 80 mg/4 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; citric acid; polysorbate 80 - breast cancer,metastatic breast cancer,dotax is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,dotax in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,dotax in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,dotax in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by dotax in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,dotax in combination with carboplatin and trastuzuma

DOTAX docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

dotax docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol absolute - breast cancer,metastatic breast cancer,dotax is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,dotax in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,dotax in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,dotax in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by dotax in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,dotax in combination with carboplatin and trastuzuma

DOCETERE docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetere docetaxel 80 mg/4 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol absolute; polysorbate 80; citric acid - breast cancer,metastatic breast cancer,docetere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetere in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetere in combination with carbopla

DOCETAXEL-RZ docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-rz docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-rz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-rz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-rz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-rz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-rz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetaxel-rz in c

DOCETAXEL-DRLA docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-drla docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; polysorbate 80; ethanol absolute - breast cancer,metastatic breast cancer,docetaxel-drla is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-drla in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-drla in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-drla in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-drla in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetax

DOCETAXEL-DRLA docetaxel 80 mg/4 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetaxel-drla docetaxel 80 mg/4 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: polysorbate 80; ethanol absolute; citric acid - breast cancer,metastatic breast cancer,docetaxel-drla is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetaxel-drla in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetaxel-drla in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetaxel-drla in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetaxel-drla in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetax

DOCETERE docetaxel 20 mg/1 ml Concentrated Solution for Infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

docetere docetaxel 20 mg/1 ml concentrated solution for infusion vial

dr reddys laboratories australia pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: citric acid; ethanol absolute; polysorbate 80 - breast cancer,metastatic breast cancer,docetere is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed.,docetere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.,docetere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease,adjuvant treatment of breast cancer,docetere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer.,doxorubicin and cyclophosphamide followed by docetere in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2,docetere in combination with carbopla